RSV Immunization: A Guide for Pregnancy & Infants

The landscape of respiratory syncytial virus (RSV) prevention for infants has shifted significantly, with new recommendations focusing on the critical role of timing for both maternal vaccination and infant immunization. As of August 2025, health officials are emphasizing that either maternal RSV vaccination during pregnancy or direct infant immunization with a monoclonal antibody is recommended to prevent severe RSV disease. Understanding when to utilize these options is now a central component of protecting the most vulnerable – newborns and young babies – from the potentially serious consequences of RSV infection.

Protecting Infants: Two Paths, Precise Timing

RSV is a common virus that typically causes mild, cold-like symptoms. However, for infants, especially those under six months old, it can lead to bronchiolitis and pneumonia, frequently requiring hospitalization. In the United States, RSV is the most common reason for infant hospitalization. Fortunately, two primary strategies are now available to mitigate this risk: vaccination of the mother during pregnancy, and direct immunization of the infant with a monoclonal antibody. These are generally not used together; the choice depends on individual circumstances and, crucially, timing.

For pregnant individuals, the Pfizer vaccine, Abrysvo, is recommended between 32 and 36 weeks of gestation. This timing is deliberate. Administering the vaccine during this window allows the mother’s body to create antibodies that are then passed to the fetus before birth, and continue to be transferred to the baby through breast milk. This provides the newborn with some level of protection for the first six months of life. The American College of Obstetricians and Gynecologists (ACOG) emphasizes the safety and effectiveness of this approach, encouraging expectant mothers to discuss both options with their healthcare providers.

Alternatively, infants can receive a dose of nirsevimab or clesrovimab, a lab-created antibody that directly protects against RSV. This is not a vaccine; it doesn’t stimulate the immune system, but rather provides immediate, passive immunity. The Centers for Disease Control and Prevention (CDC) recommends this antibody for infants younger than 8 months born during or entering their first RSV season – typically fall through spring – particularly if the mother wasn’t vaccinated during pregnancy, the mother’s vaccination status is unknown, or the infant was born within 14 days of maternal vaccination.

The October-March Window and Birth Timing

The optimal timing for infant antibody administration is generally shortly before the RSV season begins, ideally in October or November. However, a crucial nuance exists for babies born during the RSV season (October through March). In these cases, the CDC recommends administering the antibody ideally during the birth hospitalization, offering immediate protection from day one. This is particularly important as maternal antibodies passed during pregnancy offer diminishing protection over the first few months of life.

The geographic considerations are as well important. While the CDC notes that antibody administration is recommended during October through March in most of the U.S., local RSV activity can vary. Healthcare providers should consider regional patterns when making recommendations.

Monoclonal Antibodies vs. Vaccines: Understanding the Difference

It’s important to understand that nirsevimab and clesrovimab are monoclonal antibodies, not vaccines. Vaccines work by training the body’s immune system to recognize and fight off a specific pathogen. Monoclonal antibodies, provide a direct supply of antibodies, offering immediate, but temporary, protection. They don’t require the body to mount its own immune response. This distinction is key to understanding why timing is so critical for the antibody approach – the protection is immediate but wanes over time.

Both approaches – maternal vaccination and infant antibody administration – have demonstrated high effectiveness in preventing RSV-associated hospitalization. Side effects from the infant antibody are typically mild, such as pain, redness, or swelling at the injection site, and resolve quickly. While hypersensitivity reactions are uncommon, they have been reported with similar antibody products, highlighting the importance of administration in a setting where such reactions can be managed.

Navigating Patient Preferences and Healthcare Provider Discussions

Healthcare providers are encouraged to discuss both the maternal RSV vaccine and infant RSV antibodies with parents, taking into account individual patient preferences when deciding which product is best for their family. The decision isn’t simply a medical one; factors like ease of access, personal beliefs, and the health of the pregnancy all play a role. Open communication between healthcare providers and families is paramount.

What to Expect in Future Guidance

The recommendations surrounding RSV immunization are likely to evolve as more data become available. Ongoing surveillance of RSV activity, coupled with continued monitoring of vaccine and antibody effectiveness, will inform future guidance updates. The CDC and ACOG will likely refine their recommendations based on real-world data and emerging research. The development of new RSV vaccines and antibodies is ongoing, potentially offering additional options for prevention in the future. It’s crucial for healthcare professionals and the public to stay informed about the latest updates from these authoritative sources.

For parents and expectant parents, the key takeaway is to proactively discuss RSV prevention options with their healthcare provider. Understanding the timing considerations for both maternal vaccination and infant immunization is essential for making informed decisions and protecting their little ones from the potentially serious effects of this common virus.